The Motley Fool, founded in 1993 by brothers David and Tom Gardner, is a multimedia financial services company dedicated to empowering individual investors with accessible, actionable advice. Headquartered in Alexandria, Virginia, the company offers a range of products, including stock recommendations, investment research, and personal finance guidance, through its popular website, newsletters, podcasts, and premium subscription services.
Maze Therapeutics' Senior Vice President of Finance sold shares towards the end of January 2026, all while the company's stock had one of the best first-year performances of a biopharmaceutical company.
Beam Therapeutics specializes in gene-editing medicines, and recently, the company's Senior Vice President edited out thousands of shares from her portfolio.
Sandisk stock increased 16x in the past year as demand for artificial intelligence infrastructure led to a severe supply shortage in memory chips and storage devices.
The CEO of this leading medical diagnostic company sold shares throughout multiple days in January. But the manner in which the shares were sold shouldn't concern investors.
This top executive at Harmony Biosciences previous sold all of his direct shares in the company in early January 2026. But towards the end of the month, some options and restricted stock units vested, and everything changed.
The Chief Scientific Officer of Scholar Rock Holding Corp has made multiple filings regarding disposals in January 2026, but this should not alarm investors.
The Chief Scientific Officer of this biopharmaceutical company sold 20,000 shares in mid-January 2026, amid the company's stock rising 71% throughout the month.
The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple.
A Co-CEO of a leading neurotherapeutics developer reported significant insider selling amid a year of standout stock performance. But the sale is not what it seems.
A director at one of the top clinical-stage biotech companies sold 6,000 insider shares towards the end of January 2026 amid the company's stock having an underwhelming performance in 2025.
One of the top executives at a leading cloud software company exercised options in mid-January 2026, resulting in the sale of over 100,000 shares. This comes at a time when the company's stock had a strong performance throughout the month.
One of the top Ivy League schools in the country has a robust investment portfolio and recently made a major investment in this popular financial services app.
This investment firm recently sold over $6 million in shares of one of Pacer's top large-cap ETFs. Is CMC slowing down the pace of its large-cap investments?
The VictoryShares Free Cash Flow ETF is one of the leading large-cap ETFs in the U.S., and this investment firm celebrated a victory of its own by selling over one million shares of the fund.
The Chief Legal Officer of a leading fiber optic manufacturer sold thousands of shares to close out the month of January 2026. And while the stock has been performing well, there's room for concern.
